AFXN Stock Chart & Stats
$1350.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1350.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,350.00 - $1,350.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$53.64B
Enterprise Value$2.72K
Total Cash (Recent Filing)$23.90M
Total Debt (Recent Filing)$617.55M
Price to Earnings (P/E)21.1
Beta-0.10
Next Earnings
Aug 06, 2026EPS Estimate
8.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.36
Shares Outstanding89,440,570
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.32
Price to Book (P/B)1.74
Price to Sales (P/S)1.66
P/FCF Ratio21.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$543.43Price Target Upside-59.75% Downside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)25.25
Revenue Forecast (FY)$43.25B
Bulls Say, Bears Say
Bulls Say
Healthy Balance SheetLow leverage and a robust equity ratio provide durable financial flexibility. This reduces refinancing risk, allows steadier funding for R&D, product development and targeted M&A, and helps the company weather procedure-volume cyclicality without impairing strategic investments.
Aftermarket & Recurring RevenuesRecurring revenues from consumables, service contracts and software tied to an installed base increase cash flow visibility and margin stability. This lessens reliance on lumpy hardware sales, supports higher lifetime customer value and improves predictability across upgrade cycles.
Positive Operating Cash GenerationConsistent positive operating cash flow indicates core operations generate cash to fund working capital, reinvestment and maintenance capex. Even if FCF is under pressure, stable OCF underpins the business's ability to finance growth initiatives and sustain service levels.
Bears Say
Margin CompressionDeclining net, EBIT and EBITDA margins point to structural pressure on profitability—whether from pricing, higher input costs, or mix shifts. Persistent margin erosion reduces cash available for reinvestment, shareholder returns and weakens long-term return on equity.
Falling Free Cash Flow GrowthA drop in free cash flow growth and a lower FCF-to-net-income ratio constrains strategic optionality. Over time this limits capital for R&D, inorganic growth or sustained dividend/share repurchases and may force greater reliance on external financing for expansion.
Mixed/soft Revenue TrendInconsistent top-line trends—negative recent revenue-growth metric versus a small single-year uptick—suggest cyclical demand or market-share pressure. Slower, uneven revenue expansion limits operating leverage, hinders scaling benefits, and raises execution risk for longer-term growth targets.
Carl Zeiss Meditec News
AFXN FAQ
What was Carl Zeiss Meditec’s price range in the past 12 months?
Carl Zeiss Meditec lowest stock price was $1350.00 and its highest was $1350.00 in the past 12 months.
What is Carl Zeiss Meditec’s market cap?
Carl Zeiss Meditec’s market cap is $53.64B.
When is Carl Zeiss Meditec’s upcoming earnings report date?
Carl Zeiss Meditec’s upcoming earnings report date is Aug 06, 2026 which is in 5 days.
How were Carl Zeiss Meditec’s earnings last quarter?
Carl Zeiss Meditec released its earnings results on May 12, 2026. The company reported $9.006 earnings per share for the quarter, beating the consensus estimate of $7.565 by $1.441.
Is Carl Zeiss Meditec overvalued?
According to Wall Street analysts Carl Zeiss Meditec’s price is currently Overvalued.
Does Carl Zeiss Meditec pay dividends?
Carl Zeiss Meditec does not currently pay dividends.
What is Carl Zeiss Meditec’s EPS estimate?
Carl Zeiss Meditec’s EPS estimate is 8.21.
How many shares outstanding does Carl Zeiss Meditec have?
Carl Zeiss Meditec has 89,440,570 shares outstanding.
What happened to Carl Zeiss Meditec’s price movement after its last earnings report?
Carl Zeiss Meditec reported an EPS of $9.006 in its last earnings report, beating expectations of $7.565. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Carl Zeiss Meditec?
Currently, no hedge funds are holding shares in MX:AFXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Carl Zeiss Meditec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$543.43 (-59.75% Downside)
$543.43 (-59.75% Downside)
Insider Transactions
Bought Shares
Worth €51.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.99%
12-Months-Change
Fundamentals
Return on Equity
2.26%
Trailing 12-Months
Asset Growth
-3.91%
Trailing 12-Months
Company Description
Carl Zeiss Meditec
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
AFXN Stock 12 Month Forecast
Average Price Target
$543.43
▼(-59.75% Downside)